Bayer



Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com

Q4 2004 Consensus Estimates

Ladies and Gentlemen,

We would like to thank you for providing us with your Q4 2004 estimates for Bayer. The calculated consensus is based on estimates contributed by 21 major banks. All consensus numbers are quoted in million Euros.

	<u>Average</u>	High / Low
Sales	7,273	7,669 / 6,770
Underlying EBIT	335	470 / 95
Reported EBIT	277	385 / 156
Pre-tax income	88	183 / -89
Reported Net Income	34	113 / -130
EPS (Euro/share)	0.05	0.15 / -0.18

Following the new German legislation (Anlegerschutzverbesserungsgesetz/Law to improve the protection of investors) Bayer has decided to change its publication policy.

Key preliminary group figures for fiscal year 2004 will now be published on 2 March 2005 at 8:00 a.m. (CET). Bayer's full Q4 2004 figures will be published on 15 March 2005.

Best regards,

Bayer AG Investor Relations Team

Leverkusen, 24 February 2005

Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Consensus earnings estimates are based on earnings projections made by securities analysts who cover Bayer. Any opinions, forecasts, estimates, projections or predictions regarding Bayer's performance made by the analysts (and, therefore, the Consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of Bayer or its management. Bayer does not by providing these estimates imply its endorsement of or concurrence with such information, conclusions or recommendations. Bayer assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.